Breast Cancer
The Pharma Data
JUNE 7, 2023
TrodelvyĀ® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer Gilead Sciences, Inc. 0.95]; nominal p=0.0133). The European Medicines Agency has also validated a Type II Variation Marketing Authorization Application for Trodelvy in HR+/HER2- metastatic breast cancer.
Let's personalize your content